KDR and cancer: DCBLD2 is also known to modulate signaling of receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptor 2 (VEGFR2) and platelet derived growth factor receptor β (PDGFRβ) in blood vessel development and repair (3, 4, 5), insulin receptor (INSR) in glucose homeostasis (6), and epidermal growth factor receptor (EGFR) in oncogenesis and cancer progression (7, 8).